CAN IMMUNE CHECKPOINT INHIBITORS BE SAFELY USED IN PATIENTS WITH MALIGNANCY AND SEVERE DERMATOMYOSITIS?

被引：0
|
作者：
Pietsch, David [1 ]
Bigby, Kieron [2 ]
Hennessey, Ashleigh [1 ]
机构：
[1] Royal Brisbane Womens Hosp, Dept Rheumatol, Herston, Qld, Australia
[2] Redcliffe Hosp, Dept Med Oncol, Redcliffe, Qld, Australia
来源：
INTERNAL MEDICINE JOURNAL | 2022年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P68
引用
收藏
页码：34 / 34
页数：1
相关论文
共 50 条
  • [41] Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and
    Gauci, Marie-Lea
    Baroudjian, Barouyr
    Bederede, Ulysse
    Zeboulon, Charlotte
    Delyon, Julie
    Allayous, Clara
    Madelaine, Isabelle
    Eftekhari, Pirayeh
    Resche-Rigon, Matthieu
    Pote, Nicolas
    Paradis, Valerie
    Durand, Francois
    Lebbe, Celeste
    Roux, Olivier
    Bouattour, Mohamed
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2021, 45 (02)
  • [42] Peripheral lymphocyte fluctuation as an indicator of severe immune-related adverse events in patients treated with immune checkpoint inhibitors
    Haraguchi, Masafumi
    Nakao, Yasuhiko
    Narita, Syouhei
    Matsumoto, Kousuke
    Fukushima, Masanori
    Sasaki, Ryu
    Honda, Takuya
    Miuma, Satoshi
    Miyaaki, Hisamitsu
    Nakao, Kazuhiko
    CANCER MEDICINE, 2023, 12 (09): : 10636 - 10646
  • [43] Severe ototoxicity associated with immune checkpoint inhibitors (ICI) in advanced melanoma
    Boutros, Celine
    Peres, Etienne
    Routier, Emilie
    Robert, Caroline
    Le Pajolec, Christine
    EUROPEAN JOURNAL OF CANCER, 2022, 173 : 204 - 206
  • [44] Severe pseudomembranous keratoconjunctivitis with deterioration of eyesight induced by immune checkpoint inhibitors
    Urasaki, Tetsuya
    Nishizawa, Masatoshi
    Yoshida, Atsushi
    Tomomatsu, Junichi
    Yuasa, Takeshi
    Yonese, Junji
    Takahashi, Shunji
    IMMUNOTHERAPY, 2022, 14 (03) : 173 - 178
  • [45] Neurologic complications of immune checkpoint inhibitors in cancer patients
    Youssef, Michael
    Woodman, Karin
    NEUROLOGY, 2018, 90
  • [46] ALTERNATION OF GUT MICROBIOTA IN PATIENTS WITH IMMUNE CHECKPOINT INHIBITORS
    Hirata, Yuki
    Tanaka, Yoshiki
    Numa, Keijiro
    Kawasaki, Yuka
    Kinoshita, Naohiko
    Koshiba, Ryoji
    Sakiyama, Naokuni
    Kakimoto, Kazuki
    Takeuchi, Toshihisa
    Miyazaki, Takako
    Nakamura, Shiro
    Higuchi, Kazuhide
    GASTROENTEROLOGY, 2022, 162 (07) : S1001 - S1001
  • [47] Safety and efficacy of immune checkpoint inhibitors in elderly patients
    Mailly-Giacchetti, Leah
    Lopez-Trabada, Daniel
    Feldman, Judith
    Andre, Thierry
    Cohen, Romain
    BULLETIN DU CANCER, 2023, 110 (11) : 1204 - 1214
  • [48] Infections in patients receiving immune checkpoint inhibitors.
    Sae-Tia, Sutthichai
    Naidoo, Jarushka
    Mehta, Seema
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [49] Immune checkpoint inhibitors for Indian patients: A note of caution
    Venniyoor, A.
    INDIAN JOURNAL OF CANCER, 2016, 53 (03) : 468 - 469
  • [50] Toxicity management in patients treated with immune checkpoint inhibitors
    Rothschild, S., I
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 147 - 148
12345